Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Company

Santen Pharmaceutical Launches New Plant Construction in Suzhou

Fineline Cube Sep 28, 2022

Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...

Company Drug

Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma

Fineline Cube Sep 28, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...

Company Deals

Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development

Fineline Cube Sep 28, 2022

Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...

Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Company Drug

NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 28, 2022

The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 28, 2022

SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...

Company Drug

Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China

Fineline Cube Sep 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia

Fineline Cube Sep 28, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Deals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Fineline Cube Sep 28, 2022

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...

Company Drug

Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China

Fineline Cube Sep 28, 2022

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...

Company Drug

Fosun Pharma Launches 20ml SPSB Liquid Product in US Market

Fineline Cube Sep 28, 2022

Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...

Company

Merck’s Gabor Outlines AI and Biomedicine Strategy in China

Fineline Cube Sep 28, 2022

Allan Gabor, president of Merck KGaA China and executive vice president of Merck Electronics, shared...

Company Deals

Luye Pharma Grants ICI Pakistan Distribution Rights for Schizophrenia Drug Seroquel

Fineline Cube Sep 28, 2022

China-based Luye Pharma Group has reportedly handed over the distribution and marketing rights for its...

Company Medical Device

Sino Medical Sciences Gains Approval for Drug-Eluting Stent System

Fineline Cube Sep 27, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received market...

Company Drug

Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China

Fineline Cube Sep 27, 2022

The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...

Company Drug

Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study

Fineline Cube Sep 27, 2022

China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...

Company

YiChang HEC Reports Strong Recovery in 2022 Interim Results

Fineline Cube Sep 27, 2022

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...

Posts pagination

1 … 665 666 667 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.